Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1268-1278

  Wolska, Anna ^a,b   Cebula Obrzut, Barbara ^a,b   Smolewski, Piotr ^a,b   Robak, Tadeusz ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Chronic lymphocytic leukemia; Cladribine; Imiquimod; IRS 954; ODN 2006; Oligodeoxynucleotides; Toll like receptors

Indexed keywords

CD28 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CLADRIBINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; OLIGODEOXYNUCLEOTIDE 2006; OLIGODEOXYNUCLEOTIDE DERIVATIVE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CLADRIBINE; CYTOKINES; DNA; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TUMOR CELLS, CULTURED;

EID: 84877766547     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.741233     Document Type: Article

References (42)

1. Dazzi F, D ' Andrea E, Biasi G, et al . Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens . Clin Immunol Immunopathol 1995; 75 : 26 - 32.
2. Rozkov áD, Novotn áL, Pytl ík R, et al . Toll-like receptors on B-CLL cells: Expression and functional consequences of their stimulation . Int J Cancer 2010 ; 126 : 1132 - 1143.
3. Grandjenette C, Kennel A, Faure GC, et al . Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007; 92: 1279- 1281.
4. Spaner DE, Shi Y, White D, et al . Immunomodulatory eff ects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 286- 295.
5. T omic J., W hite D, S hi Y, et a l. S ensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity . J Immunol 2006; 176 : 3830 - 3839.
6. S hi Y, W hite D, H e L, et a l. D E. T oll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents . Cancer Res 2007; 67 : 1823 - 1831.
7. Hammadi A, Billard C, Faussat AM, et al . Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation . Nitric Oxide 2008; 19 : 138 - 145.
8. Spaner DE, Shi Y, White D, et al . A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia . Leukemia 2010; 24 : 222 - 226.
9. Spaner DE, Miller RL, Mena J, et al . Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod . Leuk Lymphoma 2005; 46 : 935 - 939.
10. Jahrsdörfer B, Hartmann G, Racila E, et al . CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens . J Leukoc Biol 2001; 69: 81- 88.
11. Jahrsdörfer B, M ühlenhoff L, B lackwell S E, et a l. B -cell lymphomas diff er in their responsiveness to CpG oligodeoxynucleotides . Clin Cancer Res 2005; 11: 1490- 1499.
12. Liang X, Moseman EA, Farrar MA, et al . Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells . Blood 2010; 115 : 5041 - 5052.
13. Jahrsdörfer B, Wooldridge JE, Blackwell SE, et al . Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells . J Leukoc Biol 2005; 77: 378- 387.
14. C hen L, P ark S M, T umanov A V, et a l. C D95 promotes tumour growth . Nature 2010; 465 : 492 - 496.
15. Krieg AM, Wu T, Weeratna R, et al . Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs . Proc Natl Acad Sci USA 1998; 95 : 12631 - 12636.
16. Barrat FJ, Meeker T, Gregorio J, et al . Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus . J Exp Med 2005; 202: 1131- 1139.
17. Zhu FG, Reich CF, Pisetsky DS . Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol 2002; 72 : 1154 - 1163.
18. C hen Y, L enert P, W eeratna R, et a l. I dentifi cation of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs . Gene Ther 2001; 8 : 1024 - 1032.
19. Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al . Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus . J Am Soc Nephrol 2007; 18 : 1721 - 1731.
20. Barrat FJ, Meeker T, Chan JH, et al . Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms . Eur J Immunol 2007; 37 : 3582 - 3586.
21. G uiducci C, T ripodo C, G ong M, et a l. A utoimmune skin infl ammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9 . J Exp Med 2010; 207 : 2931 - 2942.
22. G hia P, S cielzo C, F renquelli M, et a l. F rom normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 2007; 7: 127- 131.
23. A rvaniti E, N toufa S, P apakonstantinou N, et a l. T oll-like receptor signaling pathway in chronic lymphocytic leukemia: Distinct gene expression profi les of potential pathogenic signifi cance in specifi c subsets of patients . Haematologica 2011; 96 : 1644 - 1652.
24. H allek M, C heson B D, C atovsky D, et a l. ; I nternational Workshop on Chronic Lymphocytic Leukemia . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines . Blood 2008 ; 111 : 5446 - 5456.
25. Ramsay AG, Johnson AJ, Lee AM, et al . Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug . J Clin Invest 2008; 118 : 2427 - 2437.
26. D ecker T, S chneller F, S parwasser T, et a l. I mmunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95 : 999 - 1006.
27. M aruyama R, Y amana K, I toi T, et a l. A bsence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma . Br J Cancer 2006; 95 : 1244 - 1249.
28. Berman B, Sullivan T, De Araujo T, et al . Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle . Br J Dermatol 2003; 149(Suppl. 66): 59- 61.
29. Riches JC, Ramsay AG, Gribben JG . T-cell function in chronic lymphocytic leukaemia . Semin Cancer Biol 2010; 20: 431- 438.
30. B uhmann R, N olte A, W esthaus D, et a l. C D40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates diff erent types of eff ector cells . Blood 1999; 93 : 1992 - 2002.
31. Gitelson E, Hammond C, Mena J, et al . Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines . Clin Cancer Res 2003; 9: 1656- 1665.
32. Lavrik IN, Golks A, Riess D, et al . Analysis of CD95 threshold signaling: Triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling . J Biol Chem 2007; 282 : 13664 - 13671.
33. Fayad L, Keating MJ, Reuben JM, et al . Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome . Blood 2001; 97 : 256 - 263.
34. Ferrajoli A, Keating MJ, Manshouri T, et al . The clinical signifi cance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia . Blood 2002; 100: 1215- 1219.
35. Caligaris-Cappio F . Infl ammation, the microenvironment and chronic lymphocytic leukemia . Haematologica 2011; 96: 353- 355.
36. Yan XJ, Dozmorov I, Li W, et al . Identifi cation of outcomecorrelated cytokine clusters in chronic lymphocytic leukemia . Blood 2011; 118 : 5201 - 5210.
37. Robak T . Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies . TransfusApher Sci 2005; 32: 33- 44.
38. Jahrsdörfer B, Jox R, M ühlenhoff L et al . Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatoryCpG ODN . J Leukoc Biol 2002 ; 72 : 83 - 92.
39. D eaglio S, V aisitti T, A ydin S, et a l. C D38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007; 110 : 4012 - 4021.
40. Giannopoulos K, W ł asiuk P, Dmoszy ńska A, et al . Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia . Folia Histochem Cytobiol 2011; 49 : 161 - 167.
41. T romp J M, T onino S H, E lias J A, et a l. D ichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavychain- mutated versus unmutated CLL cells upon CD40/TLR9 triggering . Oncogene 2010; 29: 5071- 5082.
42. Ntoufa S, Vardi A, Papakonstantinou N, et al . Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors . Mol Med 2012 Mar 19 . [Epub ahead of print]